Laboratorios Farmaceuticos Rovi, S.A.

Equities

ROVI

ES0157261019

Pharmaceuticals

Market Closed - BME 12:35:39 2024-03-28 pm EDT After market 04:29:02 pm
80.9 EUR +0.31% Intraday chart for Laboratorios Farmaceuticos Rovi, S.A. 81 +0.12%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Rovi, Partners to Form Entity for Advanced Therapies R&D MT
Rovi explores sale of unit that makes drugs for third parties RE
Rovi Responds to Press Speculation Regarding Contract Development Business Deal MT
Transcript : Laboratorios Farmaceuticos Rovi, S.A., 2023 Earnings Call, Feb 27, 2024
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
US FDA finds control lapses at Moderna manufacturing plant RE
Italy, Spain stocks hit peaks after over 20% rally in 2023 RE
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Transcript : Laboratorios Farmaceuticos Rovi, S.A., H1 2023 Earnings Call, Jul 26, 2023
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021. CI
Global markets live: Macy's, Salesforce, Dollar General, Nordstrom, Exxon... Our Logo
Laboratorios Farmaceuticos Rovi Denies Receiving Unlawful Public Grants MT
Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021. CI
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Laboratorios Farmaceuticos Rovi, S.A. Proposes Dividend for the Year 2022 CI
Transcript : Laboratorios Farmaceuticos Rovi, S.A., 2022 Earnings Call, Feb 21, 2023
Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021. CI
ROVI Submits Final Responses to US FDA over Risvan Marketing Authorization Application MT
Transcript : Laboratorios Farmaceuticos Rovi, S.A. - Analyst/Investor Day
Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021. CI
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Transcript : Laboratorios Farmaceuticos Rovi, S.A., H1 2022 Earnings Call, Jul 27, 2022
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Chart Laboratorios Farmaceuticos Rovi, S.A.
More charts
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows: - pharmaceutical products manufactured under contract (49%); - prescription pharmaceuticals (45%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.; - diagnostic products (6%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals. Net sales break down by source of revenue between sales of products (50.6%), sales of services (49.3%) and sales of licenses (0.1%). Net sales are distributed geographically as follows: Spain (33%), European Union (17.3%), OECD countries (45.9%) and other (3.8%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
80.9 EUR
Average target price
75.68 EUR
Spread / Average Target
-6.46%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Laboratorios Farmaceuticos Rovi, S.A. - BME
  4. News Laboratorios Farmaceuticos Rovi, S.A.
  5. Laboratorios Farmaceuticos Rovi S A : Rovi To Upgrade Spanish Facility To Boost Moderna's COVID-19 Vaccine Production